Skip to main content

Table 5 Clinical outcome and length of treatment in TDM and non-TDM groups, further separated by presence or absence of renal impairment (RI or non-RI groups)

From: Proposal of initial and maintenance dosing regimens with linezolid for renal impairment patients

Total

TDM group, n = 56 (47.5%)

Non-TDM group, n = 62 (52.5%)

P-value

Recovery, n (%)

38 (67.9)

35 (56.5)

0.26

Duration of linezolid treatment (days), median (IQR)

30 (19.5–45)

12 (9–21.3)

< 0.0001

Failure, n (%)

14 (25.0)

27 (43.6)

0.052

Failure due to persistence of infection, n (%)

6 (10.7)

2 (3.2)

0.15

Failure due to hematological toxicity, n (%)

10 (17.9)

18 (29.0)

0.20

Failure due to other toxicity, n (%)

3 (5.4)

8 (12.9)

0.21

Thirty-day reinfection, n (%)

5 (8.9)

4 (6.5)

0.73

Thrombocytopenia

32 (66.7)

16 (33.3)

0.0007

RI group

TDM group, n = 21, (60.0%)

Non-TDM group, n = 14, (40.0%)

P-value

Recovery, n (%)

15 (71.4)

5 (35.7)

0.080

Duration of linezolid treatment (days), median (IQR)

34 (20–46)

11.5 (8.8–13.3)

< 0.0001

Failure, n (%)

3 (14.3)

9 (64.3)

0.0038

Failure due to persistence of infection, n (%)

1 (4.8)

0 (0.0)

1.00

Failure due to hematological toxicity, n (%)

2 (9.5)

8 (57.1)

0.0056

Failure due to other toxicity, n (%)

0 (0.0)

2 (14.3)

0.15

Thirty-day reinfection, n (%)

3 (14.3)

1 (7.1)

0.64

Thrombocytopenia

17 (81.0)

5 (35.7)

0.012

Non-RI group

TDM group, n = 35 (42.2%)

Non-TDM group, n = 48 (57.8%)

P-value

Recovery, n (%)

23 (65.7)

30 (62.5)

0.82

Duration of linezolid treatment (days), median (IQR)

29 (19–45)

13.5 (9–22.8)

< 0.0001

Failure, n (%)

18 (37.5)

11 (31.4)

0.64

Failure due to persistence of infection, n (%)

2 (4.2)

5 (14.3)

0.13

Failure due to hematological toxicity, n (%)

10 (20.8)

8 (22.9)

1.00

Failure due to other toxicity, n (%)

6 (12.5)

3 (8.6)

0.73

Thirty-day reinfection, n (%)

3 (6.3)

2 (5.7)

1.00

Thrombocytopenia

15 (42.9)

11 (22.9)

0.060

  1. Abbreviations: TDM therapeutic drug monitoring, RI renal impairment